期刊
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
卷 42, 期 13, 页码 2021-2028出版社
SPRINGER
DOI: 10.1007/s00259-015-3118-2
关键词
RGD peptide; Alfatide II; Integrin; PET/CT; Brain metastasis
资金
- National Basic Research Program of China (973 program) [2013CB733802, 2014CB744503]
- National Natural Science Foundation [81028009, 81171399, 51473071, 81472749, 81401450, 81471691]
- National Significant New Drugs Creation Program [2012ZX09505-001-001]
- Jiangsu Province Foundation [BE2012622, BL2012031, BM2012066, BE2014609]
- Outstanding Professional Fund of Health Ministry in Jiangsu Province [RC2011095, Q201406]
- Wuxi Social Development Project [CSZON1320]
- Wuxi Hospital Management Center Project [YGZXL1316]
- Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)
Purpose We report the biodistribution and radiation dosimetry of an integrin alpha(v)beta(3) specific PET tracer F-18-AlF-NOTA-E[PEG(4)-c(RGDfk)](2)) (denoted as F-18-Alfatide II). We also assessed the value of F-18-Alfatide II in patients with brain metastases. Methods A series of torso (from the skull to the thigh) static images were acquired in five healthy volunteers (3 M, 2 F) at 5, 10, 15, 30, 45, and 60 min after injection of F-18-Alfatide II (257 +/- 48 MBq). Regions of interest (ROIs) were drawn manually, and the time-activity curves (TACs) were obtained for major organs. Nine patients with brain metastases were examined by static PET imaging with F-18-FDG (5.55 MBq/kg) and F-18-Alfatide II. Results Injection of F-18-Alfatide II was well tolerated in all healthy volunteers, with no serious tracer-related adverse events found. F-18-Alfatide II showed rapid clearance from the blood pool and kidneys. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0277 +/- 0.003 mSv/MBq and 0.0198 +/- 0.002 mSv/MBq, respectively. The organs with the highest absorbed dose were the kidneys and the spleen. Nine patients with 20 brain metastatic lesions identified by MRI and/or CT were enrolled in this study. All 20 brain lesions were visualized by F-18-Alfatide II PET, while only ten lesions were visualized by F-18-FDG, and 13 by CT. Conclusion F-Alfatide II is a safe PET tracer with a favorable dosimetry profile. The observed ED suggests that F-18-Alfatide II is feasible for human studies. F-18-Alfatide II has potential value in finding brain metastases of different cancers as a biomarker of angiogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据